Article Figures & Data
- Supplementary Methods - Supplementary Methods includes additional details on these topics: tumors eligible for dose escalation phase; tumors eligible for dose expansion phase; patients enrolled using a local laboratory; study design and participants; additional inclusion criteria; full list of exclusion criteria; study treatment; study procedures; pharmacodynamic (PD) analysis; inhibition of PBMC PARP activity.
- Supplementary Figure S1 - Supplementary Figure S1. Talazoparib inhibition of PBMC PARP activity.
- Supplementary Table S1 - Supplementary Table S1. Dose-response and exposure-response parameters.